Product Profiles: Marketed Antibacterials - Increasing Genericization and Fragmentation Shape a Crowded Market

NEW YORK, Jan. 17, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760645/Product-Profiles-Marketed-Antibacterials---Increasing-genericization-and-fragmentation-shape-a-crowded-market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Introduction

In the last two years, several leading antibacterials lost patent protection, including broad-spectrum drugs Levaquin, Zosyn, and Merrem. Generic incursion will significantly erode future sales for these drugs. A number of strong competitors remain that still hold patent protection, but the majority only target Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).

Features and benefits

* Comprehensive analysis of clinical trial data and assessment of clinical and commercial attractiveness for marketed antibacterials* Discussion of future strategic opportunities to achieve success in an increasingly fragmented antibacterials market

Highlights

Levaquin, the biggest-selling antibacterial globally garnering sales over $2.5bn in 2010, lost patent protection in 2011, constituting a major blow to the marketing partners Johnson & Johnson, Daiichi Sankyo and Sanofi. Datamonitor expects generic incursion to be very strong.Zyvox remains one of most successful drugs on the market to target Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Recent clinical trial data have strengthened its position as the drug of choice to treat Gram-positive nosocomial pneumonias, which may swing physician prescribing practices towards Zyvox.The anti-MRSA market will become increasingly crowded over the coming years, with the expected approval of several strong competitors. Drugs currently on the market in this sector will need to attempt to fill important treatment gaps by acquiring approval for further indications.

Your key questions answered

* Identify key drugs within the antibacterials market, success factors for leading brands, and the potential for new entrant products.* Assess strengths, weaknesses, opportunities and threats of key marketed antibacterials and how they influence clinical and commercial attractiveness.

Strategic scoping and focusDatamonitor key findingsRelated reportsOVERVIEWCatalystSummaryPRODUCT OVERVIEWKey marketed productsMARKETED PRODUCT PROFILESLevaquin/Cravit/Tavanic (levofloxacin; Johnson & Johnson/Daiichi Sankyo/Sanofi)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessZosyn/Tazocin (piperacillin/tazobactam; Pfizer/Taisho Pharmaceutical)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessZyvox (linezolid; Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessAvelox/Octegra (moxifloxacin; Bayer/Merck & Co.)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessCubicin (daptomycin; Cubist Pharmaceuticals/Novartis/Merck & Co.)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessMerrem/Meropen (meropenem; AstraZeneca/Dainippon Sumitomo Pharma)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessTygacil (tigecycline; Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessVibativ (telavancin; Theravance/Astellas Pharma)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessOther marketed antibacterialsAugmentin (amoxicillin/clavulanate acid; GlaxoSmithKline)Primaxin/Zienam/Tienam (imipenem/cilastatin; Merck & Co.)Biaxin/Klaricid/Clarith (clarithromycin; Taisho/Abbott)Zithromax/Zithromac (azithromycin; Pfizer)BIBLIOGRAPHYJournal papersWebsitesDatamonitor reportsAPPENDIXPharmaVitae Explorer databaseContributing expertsConferences attendedReport methodology

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker